With eyes on first allogeneic CAR-T approval, Precision touts 100% response in ‘small niche’ population

Precision BioSciences has grand regulatory ambitions for its lead program: first allogeneic CAR-T therapy on the market.

En route to meeting with the FDA later this year on potential registration strategy, the North Carolina biotech is out with new interim Phase I/IIa clinical data on its prized possession, dubbed PBCAR0191....

Click to view original post